An interventional study of Stress reactivity test in Takotsubo Cardiomyopathy, sponsored by The Miriam Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by The Miriam Hospital · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Takotsubo Cardiomyopathy with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Takotsubo Cardiomyopathy · United States.
Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, this one is the only one that started in 2020, is one of 6 with no phase, and was the 10th registered.
63 studies on the registry are indexed under Takotsubo Cardiomyopathy; 26 are open to participants now.
Browse Takotsubo Cardiomyopathy studies →3 of the 11 studies in Takotsubo Cardiomyopathy with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18–110
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Takotsubo Cardiomyopathy studies recruiting now, 19 (83%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2020.
This study's enrollment of 66 is close to the median of 65 across 24 interventional studies indexed under Takotsubo Cardiomyopathy.
Median enrollment 17 across the 6 interventional studies, 190 across the 5 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 8 most frequent:
The Miriam Hospital is the lead sponsor of 182 studies on the registry; 15 are open to participants now.
The Miriam Hospital has 1 study filed under Takotsubo Cardiomyopathy — fewer than ten, so there is no comparison to draw.
1 of the studies in Takotsubo Cardiomyopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03324529NYU Langone HealthAutonomic Modulation in Takotsubo Syndrome | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goals of this study are as follows:
Newly admitted patients with a validated diagnosis of Takotsubo Syndrome (TS; n=106) will be enrolled from 3 large medical centers in the Providence, Rhode Island area. Between 2 and 4 weeks after discharge, clinically stable patients will undergo an in-person comprehensive interview to identify the events proximal to the onset of TS symptoms, complete a battery of psychosocial questionnaires and undergo a validated laboratory stress protocol. Baseline and reactive changes in measures of autonomic nervous system activity (epinephrine and norepinephrine - primary outcome), and in the secondary outcomes of cardiac vagal control and left ventricular function (ejection fraction; regional and global longitudinal strain assessed with speckle tracking echocardiography) will be assessed. Echocardiographic evaluations will be repeated 12 months thereafter together with information on major adverse cerebrovascular events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stress reactivity test
Other: Stress reactivity test
The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP. Resting Baseline (BL - 10 min). The participant is instructed to rest quietly. Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked. Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP.
Mean Change (in pg/mL) in Plasma Epinephrine Levels
Blood samples for plasma epinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery Phase. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall levels.
Time frame: At baseline
Mean Change (in pg/mL) in Plasma Norepinephrine Levels
Blood samples for plasma norepinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall norepinephrine levels.
Time frame: At baseline
Change in High Frequency Power Heart Rate Variability (Hf-HRV) in Ln Msec
High frequency power heart rate variability (hf-HRV) will be determined during the stress reactivity test by averaging high frequency values for 4-min segments within each phase (Baseline, Emotion Recall), and change will be calculated (Emotion Recall minus Baseline). Data will be collected using a Digital Holter ECG Recorder - 5 Lead, 2 Channel.
Time frame: At baseline
Mean Change in Global Longitudinal Strain (GLS)
GLS will be assessed during the stress reactivity test using off-line analysis software (TomTec imaging systems) and calculated as the average left ventricular longitudinal strain across the segments obtained using apical two, three, and four-chamber views. Because myocardial contraction results in left ventricular shortening in systole, GLS is a negative value. Change will be calculated by subtracting Baseline GLS from Emotion Recall GLS.
Time frame: Baseline
Proportion of Patients With Major Adverse Cardiac and Cerebrovascular Events
Composite of death from any cause, recurrence of TS, stroke, transient ischemic attack, and myocardial infarction.
Time frame: 12 months
Participants were consecutively recruited from three large medical centers in the Providence, RI area. Recruitment occurred from September 2, 2020 through February 12, 2025. Participants were identified through a reviews of electronic medical records (EMR) at using the ICD-10 code I51.81 Participants with a confirmed diagnosis of Takotsubo syndrome received a letter inviting them to participate in the study.
| Milestone | Stress Reactivity |
|---|---|
| Started | 66 |
| Completed | 65 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Blood samples for plasma epinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery Phase. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall levels.
| pg/ml | Stress Reactivity |
|---|---|
| Mean Change (in pg/mL) in Plasma Epinephrine Levels | 11.3 ± 27.2 |
Blood samples for plasma norepinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall norepinephrine levels.
| pg/ml | Stress Reactivity |
|---|---|
| Mean Change (in pg/mL) in Plasma Norepinephrine Levels | 64.4 ± 178.8 |
High frequency power heart rate variability (hf-HRV) will be determined during the stress reactivity test by averaging high frequency values for 4-min segments within each phase (Baseline, Emotion Recall), and change will be calculated (Emotion Recall minus Baseline). Data will be collected using a Digital Holter ECG Recorder - 5 Lead, 2 Channel.
| Ln msec | Stress Reactivity |
|---|---|
| Change in High Frequency Power Heart Rate Variability (Hf-HRV) in Ln Msec | -0.06 ± 1.2 |
GLS will be assessed during the stress reactivity test using off-line analysis software (TomTec imaging systems) and calculated as the average left ventricular longitudinal strain across the segments obtained using apical two, three, and four-chamber views. Because myocardial contraction results in left ventricular shortening in systole, GLS is a negative value. Change will be calculated by subtracting Baseline GLS from Emotion Recall GLS.
| % LV shortening | Stress Reactivity |
|---|---|
| Mean Change in Global Longitudinal Strain (GLS) | -0.2 ± 2.2 |
Composite of death from any cause, recurrence of TS, stroke, transient ischemic attack, and myocardial infarction.
| Participants | Stress Reactivity |
|---|---|
| Proportion of Patients With Major Adverse Cardiac and Cerebrovascular Events | 2 |
Collected over from enrollment to end of follow-up (12 months since enrollment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stress Reactivity | 1/65 (1.5%) | 1/65 (1.5%) | 5/65 (7.7%) |
| Event | Stress Reactivity |
|---|---|
| Takotsubo Syndrome recurrenceCardiac disorders | 1/65 |
| Event | Stress Reactivity |
|---|---|
| chest pain - non cardiac originCardiac disorders | 5/65 |
1 participant withdrew from the study and was excluded from the analysis because of
| Age, Continuous(Years) | Stress Reactivity |
|---|---|
| Mean | 65.1 ± 10.1 |
| Sex: Female, Male(Participants) | Stress Reactivity |
|---|---|
| Female | 63 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | Stress Reactivity |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 61 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Education(Participants) | Stress Reactivity |
|---|---|
| less than high school diploma | 21 |
| college or some college | 37 |
| post-graduate | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data generated under the project will be shared as per National Institutes of Health (NIH) Grant Policy and Lifespan Institutional Review Board guidelines. De-identified research data will be made available in a timely manner once the main findings from the final research data set have been accepted for publication. Access to these data will be available for educational or research purposes. Data will be de-identified to avoid linkages to individual research participants and will be free of variables that could lead to deductive disclosure of the identity of individual subjects.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: De-identified research data will be made available once the main findings from the final research data set have been accepted for publication.
Access criteria: Researchers interested in obtaining the de-identified data and associated documentation (e.g. codebook) can make a request to the principal investigator. requestors will be asked to sign a data sharing agreement that includes conditions to 1) protect the identity of participants, 2) limit use of data for educational and research purposes, and 3) prevent transfer of data to other users, and 4) acknowledge the data source. The de-identified data will be shared using Excel or Statistical Package for the Social Sciences (SPSS) file formats.
Ran from Sep 2020 to primary completion in Nov 2025, 62 months.
Results were first posted in Sep 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.